drugset / Trial / NCT03018093
A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL
NaSingle-groupOpen-labelTreatment
Summary
The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR011 in treatment of adult subjects with relapsed/refractory CD19+ B cells acute lymphoblastic leukemia(r/r CD19+B-ALL)
Timeline
- Start
- 2017-01
- Primary completion
- 2018-08
- Completion
- 2018-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | C-CAR011 | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | C-CAR011 | Cell therapy | 1.5e+06 cells/kg | Intravenous |
| Subject | C-CAR011 | Cell therapy | 3e+06 cells/kg | Intravenous |